Synergistic Effects of Selective Inhibitors Targeting the PI3K/AKT/mTOR Pathway or NUP214-ABL1 Fusion Protein in Human Acute Lymphoblastic Leukemia

Thumbnail
View/ Open

Show full item record

Author
McCubrey, James A.
URI
http://hdl.handle.net/10342/9629
Subject
 NUP214-ABL1; PI3K/Akt/mTOR signaling; T-Acute Lymphoblastic Leukemia 
Date
2016-11-03
Citation:
APA:
McCubrey, James A.. (November 2016). Synergistic Effects of Selective Inhibitors Targeting the PI3K/AKT/mTOR Pathway or NUP214-ABL1 Fusion Protein in Human Acute Lymphoblastic Leukemia. Oncotarget, (7:48), p.79842-79853. Retrieved from http://hdl.handle.net/10342/9629

Display/Hide MLA, Chicago and APA citation formats.

MLA:
McCubrey, James A.. "Synergistic Effects of Selective Inhibitors Targeting the PI3K/AKT/mTOR Pathway or NUP214-ABL1 Fusion Protein in Human Acute Lymphoblastic Leukemia". Oncotarget. 7:48. (79842-79853.), November 2016. December 06, 2022. http://hdl.handle.net/10342/9629.
Chicago:
McCubrey, James A., "Synergistic Effects of Selective Inhibitors Targeting the PI3K/AKT/mTOR Pathway or NUP214-ABL1 Fusion Protein in Human Acute Lymphoblastic Leukemia," Oncotarget 7, no. 48 (November 2016), http://hdl.handle.net/10342/9629 (accessed December 06, 2022).
AMA:
McCubrey, James A.. Synergistic Effects of Selective Inhibitors Targeting the PI3K/AKT/mTOR Pathway or NUP214-ABL1 Fusion Protein in Human Acute Lymphoblastic Leukemia. Oncotarget. November 2016; 7(48) 79842-79853. http://hdl.handle.net/10342/9629. Accessed December 06, 2022.
Collections